eLetters

93 e-Letters

published between 2007 and 2010

  • Clarification of the role of ultrasonography, magnetic resonance imaging and conventional radiography in the ACR/EULAR 2010 rheumatoid arthritis classification criteria - comment to the article by Aletaha et al.
    Mikkel Ostergaard

    Dear Editor,

    With large enthusiasm I read the paper on the 2010 ACR/EULAR RA classification criteria,[1,2] which in the interest of our patients allow earlier diagnosis of rheumatoid arthritis (RA). I congratulate the authors for their hard and successfull work, which I am sure will benefit our patients.
    Being interested in imaging methods and the way they can assist rheumatologists in improving the care of patient...

    Show More
  • Re:Re:EULAR advice against DMARD combination therapy, a major flaw.
    Niels A Graudal

    Dear Editor,

    We thank Dr. Smolen for commenting our criticism. As Dr. Smolen correctly states we did not pay attention to the fact that the EULAR recommendations (1) are based on 5 different systematic reviews. However, we assumed that the authors of the recommendations would attempt to reach an unambiguous position on the basis of the different reviews. Comparing the 15 recommendations in Table 1 with the treatment al...

    Show More
  • Anti-CCP report: clinicians should be aware!
    Sai H K Murng

    Dear Sir

    The article describing '2010 Rheumatoid Arthritis Classification Criteria' is very informative and contains much useful practical guidance. However there are factual errors regarding the measurement of ACPA/CCP which ought to be corrected.

    With a high specificity anti CCP is very useful for early diagnosis of rheumatoid arthritis. [1, 2, 3] While the definition of positivity is understandably va...

    Show More
  • Microscopic polyangiitis was recognized in 1923
    Nicolo Pipitone

    Dear Editor,

    In the paper "EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis" [1] it is stated that microscopic polyangiitis (MPA) was described in 1948 [2]. In fact, the first description of MPA I know of is considerably older than that, dating back to 1923 [3].

    References

    [1] Basu N, Watts R, Bajema I et al. EULAR points to consi...

    Show More
  • Can patients with established RA stop TNF blocker therapy?
    Paul Emery

    Dear Editor,

    We read with interest the above publication which we found to be very informative.
    The article presents the results of a systemic literature review of patients with established rheumatoid arthritis (RA) (>2 years disease duration) treated with stable and effective disease modifying anti-rheumatic drug (DMARD) therapy, with a metaanalysis to determine the effect of therapy withdrawal...

    Show More
  • Long term knee OA trial design: an ounce of prevention is worth a pound of cure
    Jean-Pierre Pelletier

    Dear Editor,

    Sawitzke et al (1) reported on the results from the GAIT study assessing the long term effects of 2-year treatment on knee osteoarthritis (OA) symptoms. The findings indicate that the effects of glucosamine hydrochloride (GHCl), chondroitin sulfate (CS), and celecoxib treatment were not better than placebo, although safe and well tolerated.
    The study results are not surprising in view of the original G...

    Show More
  • Results of remission targeted therapy last longer than a year
    Vappu M. Rantalaiho

    Dear Editor,

    Gorter and collagues (1) cover elegantly the literature on the efficacy of systemic glucocorticoids (GCs) in rheumatoid arthritis (RA). Nevertheless, we would like to draw attention to an error concerning the results of the FIN-RACo Trial (2). The authors are correct when presenting the treatment strategies used in the FIN-RACo Trial and stating the implausibility of mere systemic GCs explaining the...

    Show More
  • Re:EULAR advice against DMARD combination therapy, a major flaw.
    Josef S. Smolen

    Dear Editor,

    When writing their comment on the recent EULAR recommendations for the management of RA (1), Drs. Graudal and Jurgens must have overlooked several important aspects related to these recommendations. First, the set of recommendations was based on five separate systematic literature reviews (SLRs) and, indeed, items 5, 7 and 8 quoted by them are largely based on two of these 5 SLRs (2;3) rather than,...

    Show More
  • Re:Has modified release prednisone any clinical advantage over immediate release prednisone in patients with rheumatoid arthritis?
    Johannes WJ Bijlsma

    We thank dr Bannwarth for his comments, indicating that dividing prednison treatment over the day might be as effective as using a modified release preparation. This has not been evaluated in a clinical study, so there is no evidence to support or refute this suggestion. However, the discussed modified release preparation is especially developed to target the nadir in the cortisol rhythm, which is quite different from div...

    Show More
  • Re:Intensive management of early RA leads to improvements in physical function.
    Monika Schoels

    Dear Editor,

    Thank you for your letter, and the possibility to reply. We fully appreciate the favorable HAQ outcomes of the intensive strategy arm in the TICORA study [1].
    However, based on the systematic literature search for the Treat to Target Initiative, the impact of strategic treatment on functional outcome was controversial: of the four trials that assessed functional outcome[1-4], three [2-4] stated no ben...

    Show More

Pages